Discover the needle-free diabetes treatment made for cats

Описание: • Once daily, orally administered treatment option for otherwise healthy
cats with diabetes mellitus that have not previously been treated with
insulin
Twice daily injections can be frustrating for pet owners
88% of pet owners find twice daily injections to interfere with their
schedule¹
In studies, owner success rates of dosing their cats with Bexacat
was 96-97%²
• No dose titration, regardless of blood glucose concentration or weight
of the patient (indicated for cats weighing 3.0kg or greater)

• The first sodium-glucose cotransporter 2 (SGLT2) in veterinary
medicine
Decreases blood glucose by urinary excretion of glucose
Minimal risk of hypoglycemia
In studies, average blood glucose levels decreased from 460
mg/dL to 148 mg/dL in just 8 hours on the first day of
administration
By day 56
 83% of cats were considered treatment successes
 68% of cats had improvement in polyuria
 74% of cats had improvement in polydipsia
 Mean fructosamine levels decreased from 544 μmol/L to 295
μmol/L


Indication:
Bexacat is indicated to improve glycemic control in otherwise healthy cats with diabetes mellitus not previously treated with insulin.

Important Safety Information:
Before using this product, it is important to read the entire product insert, including the boxed warning. See https://bit.ly/3khhRFJ for full prescribing information.
Cats treated with Bexacat may be at an increased risk of diabetic ketoacidosis or euglycemic diabetic ketoacidosis, both of which may result in death. Development of these conditions should be treated promptly, including insulin administration and discontinuation of Bexacat. Do not use Bexacat in cats with diabetes mellitus who have previously been treated with insulin, who are receiving insulin, or in cats with insulin-dependent diabetes mellitus. The use of Bexacat in cats with insulin-dependent diabetes mellitus, or the withdrawal of insulin and initiation of Bexacat, is associated with an increased risk of diabetic ketoacidosis or euglycemic diabetic ketoacidosis and death. Sudden onset of hyporexia/anorexia, lethargy, dehydration, diarrhea that is unresponsive to conventional therapy, or weight loss in cats receiving Bexacat should prompt immediate discontinuation of Bexacat and assessment for diabetic ketoacidosis, regardless of blood glucose level. Bexacat should not be initiated in cats with pancreatitis, anorexia, dehydration, or lethargy at the time of diagnosis of diabetes mellitus, as it may indicate the presence of other concurrent disease and increase the risk of diabetic ketoacidosis. Due to risk of severe adverse reactions, do not use Bexacat in cats with evidence of hepatic disease or reduced renal function. Consult a physician in case of accidental ingestion by humans.

References:
¹,² Elanco Animal Health. Data on File

©2023 Elanco or its affiliates. Bexacat, Elanco and the diagonal bar logo are trademarks of Elanco or its affiliates. PM-US-23-0348 Animal Health. Data on File ©2023 Elanco or its affiliates. Bexacat, Elanco and the diagonal bar logo are trademarks of Elanco or its affiliates. PM-US-23-0348